CN116509973A - Pharmaceutical composition for treating chronic obstructive pulmonary disease and application thereof - Google Patents
Pharmaceutical composition for treating chronic obstructive pulmonary disease and application thereof Download PDFInfo
- Publication number
- CN116509973A CN116509973A CN202310736383.8A CN202310736383A CN116509973A CN 116509973 A CN116509973 A CN 116509973A CN 202310736383 A CN202310736383 A CN 202310736383A CN 116509973 A CN116509973 A CN 116509973A
- Authority
- CN
- China
- Prior art keywords
- parts
- chronic obstructive
- obstructive pulmonary
- pharmaceutical composition
- pulmonary disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title claims abstract description 77
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 52
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 241000208340 Araliaceae Species 0.000 claims abstract description 12
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 12
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 12
- 235000008434 ginseng Nutrition 0.000 claims abstract description 12
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims abstract description 11
- 235000017803 cinnamon Nutrition 0.000 claims abstract description 11
- 229940107666 astragalus root Drugs 0.000 claims abstract description 6
- 241000756042 Polygonatum Species 0.000 claims abstract description 5
- 235000008737 Polygonatum biflorum Nutrition 0.000 claims abstract description 5
- 230000002685 pulmonary effect Effects 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 24
- 238000002156 mixing Methods 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 15
- 239000008187 granular material Substances 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 241001313855 Bletilla Species 0.000 claims description 7
- 241000801118 Lepidium Species 0.000 claims description 7
- 241000361919 Metaphire sieboldi Species 0.000 claims description 7
- 235000006533 astragalus Nutrition 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 241001061264 Astragalus Species 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000002386 leaching Methods 0.000 claims description 6
- 210000004233 talus Anatomy 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 241001633680 Polygonatum odoratum Species 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000007779 soft material Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 2
- 230000000414 obstructive effect Effects 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 240000002948 Ophiopogon intermedius Species 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 abstract description 12
- 210000000952 spleen Anatomy 0.000 abstract description 12
- 230000001737 promoting effect Effects 0.000 abstract description 11
- 206010061218 Inflammation Diseases 0.000 abstract description 9
- 230000004054 inflammatory process Effects 0.000 abstract description 9
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 8
- 230000036039 immunity Effects 0.000 abstract description 7
- 230000001105 regulatory effect Effects 0.000 abstract description 7
- 210000002784 stomach Anatomy 0.000 abstract description 7
- 238000005728 strengthening Methods 0.000 abstract description 7
- 210000002966 serum Anatomy 0.000 abstract description 6
- 108050003558 Interleukin-17 Proteins 0.000 abstract description 5
- -1 IL-beta Proteins 0.000 abstract description 4
- 230000001154 acute effect Effects 0.000 abstract description 4
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 4
- 230000002708 enhancing effect Effects 0.000 abstract description 4
- 230000000813 microbial effect Effects 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 4
- 102100037850 Interferon gamma Human genes 0.000 abstract description 3
- 108010074328 Interferon-gamma Proteins 0.000 abstract description 3
- 108090000978 Interleukin-4 Proteins 0.000 abstract description 3
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 3
- 210000001132 alveolar macrophage Anatomy 0.000 abstract description 3
- 230000001276 controlling effect Effects 0.000 abstract description 3
- 230000008088 immune pathway Effects 0.000 abstract description 3
- 230000007365 immunoregulation Effects 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 230000007246 mechanism Effects 0.000 abstract description 3
- 230000010287 polarization Effects 0.000 abstract description 3
- 230000028327 secretion Effects 0.000 abstract description 3
- 206010067484 Adverse reaction Diseases 0.000 abstract description 2
- 241000894006 Bacteria Species 0.000 abstract description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract description 2
- 230000006838 adverse reaction Effects 0.000 abstract description 2
- 238000002512 chemotherapy Methods 0.000 abstract description 2
- 206010017758 gastric cancer Diseases 0.000 abstract description 2
- 230000002441 reversible effect Effects 0.000 abstract description 2
- 201000011549 stomach cancer Diseases 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 25
- 210000004072 lung Anatomy 0.000 description 24
- 230000007812 deficiency Effects 0.000 description 17
- 230000000694 effects Effects 0.000 description 12
- 238000003745 diagnosis Methods 0.000 description 8
- 208000011580 syndromic disease Diseases 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 7
- 230000004199 lung function Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- 230000006641 stabilisation Effects 0.000 description 6
- 238000011105 stabilization Methods 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 108020005198 Long Noncoding RNA Proteins 0.000 description 5
- 244000248557 Ophiopogon japonicus Species 0.000 description 5
- 230000009798 acute exacerbation Effects 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000027939 micturition Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000000391 smoking effect Effects 0.000 description 4
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 3
- 102100039065 Interleukin-1 beta Human genes 0.000 description 3
- 102000018745 NF-KappaB Inhibitor alpha Human genes 0.000 description 3
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 3
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229940124630 bronchodilator Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000009325 pulmonary function Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010039424 Salivary hypersecretion Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 201000009267 bronchiectasis Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 208000026451 salivation Diseases 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- QTQGHKVYLQBJLO-UHFFFAOYSA-N 4-methylbenzenesulfonate;(4-methyl-1-oxo-1-phenylmethoxypentan-2-yl)azanium Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC(C)CC(N)C(=O)OCC1=CC=CC=C1 QTQGHKVYLQBJLO-UHFFFAOYSA-N 0.000 description 1
- 241000572565 Alpinia oxyphylla Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000045403 Astragalus propinquus Species 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 244000300022 Bauhinia malabarica Species 0.000 description 1
- 235000018906 Bauhinia malabarica Nutrition 0.000 description 1
- 241001313857 Bletilla striata Species 0.000 description 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010010305 Confusional state Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 241000243684 Lumbricus Species 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 206010029888 Obliterative bronchiolitis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241001448424 Ophiopogon Species 0.000 description 1
- 229930195210 Ophiopogon Natural products 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 102000000427 Proto-Oncogene Proteins c-jun Human genes 0.000 description 1
- 108010016131 Proto-Oncogene Proteins c-jun Proteins 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 201000003848 bronchiolitis obliterans Diseases 0.000 description 1
- 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 206010062952 diffuse panbronchiolitis Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000037080 exercise endurance Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000003958 fumigation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000011316 hemodynamic instability Diseases 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960001401 hydrocortisone sodium succinate Drugs 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000012482 interaction analysis Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a pharmaceutical composition for treating chronic obstructive pulmonary disease, which comprises the following components: ginseng, astragalus root, fructus alpiniae oxyphyllae, fragrant solomonseal rhizome, dried orange peel and cinnamon. The medicine composition can effectively play the role of immunoregulation and inflammation inhibition, and has the mechanism of reducing the expression of serum inflammatory factors TNF-alpha, IL-beta, IL-6, IFN-gamma, IL-17 and the like, promoting the secretion of anti-inflammatory factors IL-4 and IL-35 and regulating the balance of Th1/Th 2. Enhancing immunity, reducing pulmonary inflammatory reaction, reducing acute weighting times, and improving life quality. The principal strengthening and primordial qi-strengthening prescription can play a role by regulating and controlling the microecological lung-intestine axis, for example, the research shows that the spleen strengthening and stomach nourishing can increase the relative abundance of the conch bacteria and reverse adverse reactions caused by chemotherapy of gastric cancer patients. The pharmaceutical composition can regulate the expression of specific microbial flora of the microecological lung-intestinal axis by mediating the polarization of alveolar macrophages, target inflammatory immune pathways, consolidate and strengthen the immunity of organisms, and intervene in the inflammatory progress of COPD so as to treat the chronic obstructive pulmonary disease.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a pharmaceutical composition for treating chronic obstructive pulmonary disease and application thereof.
Background
Chronic obstructive pulmonary disease (Chronic Obstructive Pulmonary Disease, COPD, simply slow obstructive pulmonary) is a major disease with high global morbidity, disability rate and mortality. Chronic inflammatory reaction is a key link of the development process of COPD, and the clinical treatment modes mainly comprise glucocorticoid anti-inflammatory, bronchodilator spasmolysis, antibiotics and the like, so that the problems of dependence, repeated attack and the like are easy to generate, and the continuous decline of the lung function cannot be effectively prevented. How to break through the inflammatory bottleneck of COPD and delay the progress of the disease course of COPD has urgent demands.
Disclosure of Invention
The invention aims to provide a pharmaceutical composition for treating chronic obstructive pulmonary disease, which is used for treating the symptoms of COPD (chronic obstructive pulmonary disease) lung-kidney qi deficiency, enhancing immunity and reducing lung inflammatory reaction so as to solve the problems in the background art.
The technical problems solved by the invention are realized by adopting the following technical scheme: a pharmaceutical composition for treating chronic obstructive pulmonary disease, comprising the following components: ginseng, astragalus root, fructus alpiniae oxyphyllae, fragrant solomonseal rhizome, dried orange peel and cinnamon.
The medicine composition for treating chronic obstructive pulmonary disease comprises the following components in parts by weight: 15-25 parts of ginseng, 7-15 parts of astragalus, 7-15 parts of fructus alpiniae oxyphyllae, 7-15 parts of radix polygonati officinalis, 4-10 parts of dried orange peel and 1-5 parts of cinnamon.
The medicine composition for treating chronic obstructive pulmonary disease comprises the following components in parts by weight: 20 parts of ginseng, 10 parts of astragalus, 10 parts of fructus alpiniae oxyphyllae, 10 parts of polygonatum odoratum, 6 parts of dried orange peel and 3 parts of cinnamon.
The medicine composition for treating chronic obstructive pulmonary disease also comprises dwarf lilyturf tuber, bletilla tuber, pepperweed seed and earthworm, wherein the traditional Chinese medicine is preferably prepared from the following components in parts by weight: 10 parts of dwarf lilyturf tuber, 10 parts of common bletilla tuber, 6 parts of pepperweed seed and 8 parts of earthworm.
The application of the pharmaceutical composition in preparing the products for treating chronic obstructive pulmonary disease can be prepared into any conventional oral preparation in pharmacy, including but not limited to decoction, granules, pills, tablets, capsules, oral liquid or oral liquid.
A method for preparing a traditional Chinese medicine decoction by using a pharmaceutical composition for treating chronic obstructive pulmonary disease comprises the following steps: weighing a proper amount of medicinal composition according to the weight ratio, mixing and crushing the medicinal composition, mixing the medicinal components with water, heating and extracting, wherein the heating and extracting comprises the steps of decocting with strong fire and then decocting with slow fire for two times, mixing the decoctions, filtering the residues to obtain an extracted liquid medicine, namely the decoction.
A method for preparing traditional Chinese medicine particles by using a pharmaceutical composition for treating chronic obstructive pulmonary disease comprises the following steps: weighing a proper amount of medicinal composition according to the weight ratio, mixing and crushing the medicinal composition, mixing the medicinal components with water, heating and extracting, decocting with strong fire, decocting with slow fire for two times, mixing decoctions, filtering residues to obtain a leaching liquid medicine, concentrating the leaching liquid medicine into thick paste, drying, crushing into fine powder, adding a proper amount of sugar powder and dextrin, mixing uniformly, adding ethanol to prepare a soft material, granulating, drying and finishing to obtain the traditional Chinese medicine granules.
A method for preparing capsule from pharmaceutical composition for treating chronic obstructive pulmonary disease comprises packaging the above Chinese medicinal granule.
Compared with the prior art, the invention has the beneficial effects that: the medicine composition can effectively play the role of immunoregulation and inflammation inhibition, and has the mechanism of reducing the expression of serum inflammatory factors TNF-alpha, IL-beta, IL-6, IFN-gamma, IL-17 and the like, promoting the secretion of anti-inflammatory factors IL-4 and IL-35 and regulating the balance of Th1/Th 2. Enhancing immunity, reducing pulmonary inflammatory reaction, reducing acute weighting times, and improving life quality. The principal strengthening and primordial qi-strengthening prescription can play a role by regulating and controlling the microecological lung-intestine axis, for example, the research shows that the spleen strengthening and stomach nourishing can increase the relative abundance of the conch bacteria and reverse adverse reactions caused by chemotherapy of gastric cancer patients. The pharmaceutical composition can regulate the expression of specific microbial flora of the microecological lung-intestinal axis by mediating the polarization of alveolar macrophages, target inflammatory immune pathways, consolidate and strengthen the immunity of organisms, and intervene in the inflammatory progress of COPD so as to treat the chronic obstructive pulmonary disease.
Detailed Description
The present invention is further described below in order to make the implementation means, the creation features, the achievement purposes and the effects of the present invention easy to understand.
The embodiment provides a pharmaceutical composition for treating chronic obstructive pulmonary disease, which comprises the following components: ginseng, astragalus root, fructus alpiniae oxyphyllae, fragrant solomonseal rhizome, dried orange peel and cinnamon; the weight portion ratio of each component is as follows: 15-25 parts of ginseng, 7-15 parts of astragalus, 7-15 parts of fructus alpiniae oxyphyllae, 7-15 parts of radix polygonati officinalis, 4-10 parts of dried orange peel and 1-5 parts of cinnamon.
The preferred pharmaceutical composition for treating chronic obstructive pulmonary disease comprises the following components in parts by weight: 20 parts of ginseng, 10 parts of astragalus, 10 parts of fructus alpiniae oxyphyllae, 10 parts of polygonatum odoratum, 6 parts of dried orange peel and 3 parts of cinnamon.
The medicine composition for treating chronic obstructive pulmonary disease also comprises dwarf lilyturf tuber, bletilla tuber, pepperweed seed and earthworm, wherein the traditional Chinese medicine is preferably prepared from the following components in parts by weight: 10 parts of dwarf lilyturf tuber, 10 parts of common bletilla tuber, 6 parts of pepperweed seed and 8 parts of earthworm.
The raw materials comprise:
ginseng is warm in nature, sweet in taste, slightly bitter in flavor and slightly warm in nature. Enter spleen and lung meridians. To strengthen primordial qi, recover pulse, arrest excessive loss, invigorate spleen, benefit lung, promote fluid production and tranquilize the mind. Can be used for treating asthenia, listlessness, cold limbs, weak pulse, spleen deficiency, anorexia, lung deficiency, asthma, cough, and thirst due to body fluid deficiency.
Astragalus root is sweet in taste and slightly warm in nature; enter spleen and lung meridians. Astragalus mongholicus has the effects of tonifying qi and yang, strengthening exterior and arresting sweating, inducing diuresis and removing edema, promoting fluid production and nourishing blood, promoting the circulation of qi and relieving arthralgia, expelling toxin and expelling pus, healing sore and promoting granulation. .
Fructus Alpinae Oxyphyllae is pungent in flavor and warm in nature. Pungent and warm in nature. Warming spleen, relieving diarrhea, controlling salivation, warming kidney, reducing urination and stopping nocturnal emission. Deficiency-cold in spleen and stomach, vomiting, diarrhea, abdominal cold pain, excessive saliva and saliva, kidney deficiency, enuresis, frequent urination, spermatorrhea and turbid urine.
Rhizoma Polygonati Odorati has effects of nourishing yin, moistening dryness, promoting salivation, and quenching thirst. Yu Zhu is indicated for lung and stomach yin impairment, dryness-heat cough, dry throat, thirst, internal heat and diabetes.
Chen Pi is bitter and pungent in nature and warm in nature, and enters spleen and lung meridians. Has effects of regulating qi-flowing, invigorating spleen, eliminating dampness and resolving phlegm.
Rou Gui is pungent and sweet in nature and enters kidney, spleen, heart and liver meridians due to its excessive heat. Has effects of warming spleen and stomach, dispelling cold, regulating qi-flowing and relieving pain.
Mai Dong is sweet in flavor, slightly bitter and slightly cold. After entering heart, lung and stomach meridians, ophiopogon root has the effects of moistening lung, nourishing yin, tonifying stomach, promoting fluid production, clearing heart fire and relieving restlessness.
The bletilla striata has bitter, sweet and astringent taste, is slightly cold, and has the effects of astringing, stopping bleeding, reducing swelling and promoting granulation.
Ting Li Zi is pungent, bitter and cold in nature. Pungent and bitter in flavor and cold in nature. Purging lung and descending qi, eliminating phlegm and relieving asthma, inducing diuresis and relieving swelling, and relieving heat and eliminating pathogenic factors.
Lumbricus has effects of clearing heat, relieving spasm, promoting urination, and removing toxic substances. Has effects of clearing heat, arresting convulsion, dredging collaterals, relieving asthma, and promoting urination.
The application of the pharmaceutical composition in preparing the products for treating chronic obstructive pulmonary disease can be prepared into any conventional oral preparation in pharmacy, including but not limited to decoction, granules, pills, tablets, capsules, oral liquid or oral liquid.
The invention also aims at providing a method for preparing the traditional Chinese medicine decoction, which comprises the following steps: weighing a proper amount of medicinal composition according to the weight ratio, mixing and crushing the medicinal composition, mixing the medicinal components with water, heating and extracting, wherein the heating and extracting comprises the steps of decocting with strong fire and then decocting with slow fire for two times, mixing the decoctions, filtering the residues to obtain an extracted liquid medicine, namely the decoction.
Another object of the present invention is to provide a method for preparing the inventive Chinese medicinal granule, comprising the steps of: weighing a proper amount of medicinal composition according to the weight ratio, mixing and crushing the medicinal composition, mixing the medicinal components with water, heating and extracting, decocting with strong fire, decocting with slow fire for two times, mixing decoctions, filtering residues to obtain a leaching liquid medicine, concentrating the leaching liquid medicine into thick paste, drying, crushing into fine powder, adding a proper amount of sugar powder and dextrin, mixing uniformly, adding ethanol to prepare a soft material, granulating, drying and finishing to obtain the traditional Chinese medicine granules.
The invention also aims to provide a method for preparing the traditional Chinese medicine capsule, and the traditional Chinese medicine granule is packaged to obtain the capsule.
In the embodiment, the pharmaceutical composition treats clinical experimental study of patients with lung-kidney qi deficiency in COPD stabilization period;
and (3) collecting cases: referring to Western medicine COPD diagnosis, stage standard and traditional Chinese medicine COPD diagnosis standard, the clinical patient with COPD lung-kidney qi deficiency syndrome is included, and specific diagnosis standard and scheme are as follows:
1) Western diagnostic criteria
The relevant content customization is referred to 2022 edition global policy for chronic obstructive pulmonary disease (GOLD), respiratory science of China society of medicine, chronic obstructive pulmonary disease group, guide for diagnosis and treatment of chronic obstructive pulmonary disease (revised version of 2021), and Chinese expert consensus for diagnosis and treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) (updated version of 2017).
(1) Has dyspnea, chronic cough and expectoration symptoms;
(2) COPD has a family aggregation tendency, is frequently developed in autumn and winter cold seasons, is frequently developed with repeated respiratory tract infection and acute exacerbation history, and is more frequent along with the progress of illness;
(3) there is a persistent airflow restriction: the lung function measurement index is a necessary condition for diagnosing COPD, namely FEV1/FVC is less than 70% after bronchodilator is used;
(4) except for certain flow-restricted diseases of known etiology or with characteristic pathological manifestations, such as bronchial asthma, congestive heart failure, pulmonary tuberculosis fibrosis lesions, bronchiectasis, diffuse panbronchiolitis, pulmonary cystic fibrosis, and bronchiolitis obliterans.
2) Western medicine staging Standard
Stabilization period: the patients have stable or slight symptoms of short breath, cough, expectoration and the like, or recover to symptoms before the onset of acute exacerbation.
3) Western medicine grading Standard
COPD is classified as a grade 4 in severity of airflow limitation based on pulmonary function (FEV 1/FVC <70% and FEV1 percentage based on post bronchodilator), see in particular table 1.
TABLE 1 airflow limited severity classification
4) Diagnostic criteria for traditional Chinese medicine
Diagnosis is performed by referring to the "diagnosis and treatment guide of chronic obstructive pulmonary disease" of traditional Chinese medicine (2011 edition) made by the specialized committee of the department of medical science of Chinese medical science, the department of pulmonary diseases:
diagnosis criteria for lung and kidney Qi deficiency syndrome: (1) wheezing, shortness of breath, exacerbation with movement, (2) debilitation, or spontaneous perspiration, exacerbation with movement; (3) is easy to catch cold and averse wind; (4) soreness and weakness of waist and knees; (5) tinnitus, dizziness or facial disturbance; (6) frequent urination, nocturia, or cough with drowsiness; (7) pale tongue with white coating and deep thready or weak pulse. The method comprises 2 items (1), (2) and (3), and 2 items (4), (5), (6) and (7).
5) Case inclusion criteria
The patients in the group need to meet the following conditions simultaneously:
(1) patients who meet COPD diagnostic criteria;
(2) belonging to the stationary phase;
(3) meets the traditional Chinese medicine differentiation type standard of lung-kidney qi deficiency;
(4) age 40-75 years old;
(5) no other clinical study was enrolled 1 month prior to group entry;
(6) voluntarily receiving treatment and signing an informed consent form;
(7) antibiotics were not used a month prior to group entry.
6) Case exclusion criteria
(1) Patients with severe COPD and patients with acute phase;
(2) pregnant and lactating women;
(3) patients with mental confusion, dementia and various mental diseases;
(4) class IV cardiac function and hemodynamic instability;
(5) neuromuscular diseases affecting respiratory and motor functions, such as bronchiectasis, bronchial asthma, active tuberculosis, pulmonary embolism, pneumothorax, pleural effusion, malignant tumor, and the like;
(6) severe liver and kidney diseases (severe liver diseases refer to cirrhosis, portal hypertension and bleeding from varicose veins, severe kidney diseases include dialysis, kidney transplantation);
(7) patients with long-term bedridden patients for various reasons.
(2) Clinical grouping and administration method:
the study was divided into 2 groups, grouped as follows:
(1) control group: lung-kidney qi deficiency syndrome group in COPD stabilization phase. The control group was treated on a western medicine basis with tiotropium bromide powder inhalant (18 μg/inhalation, 30 capsules/cartridge, national drug standard: H20060454, available from the pharmaceutical company, inc. of the pharmaceutical group, day-a-c). The usage is 1 suction/time, 2 times/d. The treatment course is 6 months.
(2) Treatment group: COPD lung-kidney qi deficiency syndrome treatment group. The traditional Chinese medicine prescription is added for western medicine basic treatment, and the medicine comprises the following components: 20g of roasted astragalus root, 10g of sun-dried ginseng, 10g of fragrant solomonseal rhizome, 10g of fructus alpiniae oxyphyllae, 6g of dried orange peel, 3g of cinnamon, 10g of dwarf lilyturf tuber, 10g of common bletilla tuber, 6g of pepperweed seed and 8g of earthworm. In order to ensure quality control of the prescription, the traditional Chinese medicines are all prepared from the same batch of granules. The administration method comprises taking 100ml warm boiled water after breakfast and supper every day. The treatment course is 6 months.
The medicine composition is used for treating patients with lung-kidney qi deficiency in the COPD stabilization period, and the medicine composition is found to reduce the acute exacerbation times of the patients with lung-kidney qi deficiency in the COPD stabilization period, improve the lung function, clinical symptoms and exercise endurance of the patients, and improve mMRC grading and CAT grading compared with simple western medicine basic treatment;
(1) Pulmonary function (FEV 1, FEV 1/FVC) comparison
(2) Comparison of acute exacerbation times
(3) 6 minute walking distance (6 MWD) comparison
(4) CAT score comparison
(5) mMRC comparison
(6) Integral comparison of syndrome of Chinese medicine
(7) Western medicine symptoms and sign integral comparison
The pharmaceutical composition can be used for treating patients with lung and kidney qi deficiency at COPD stabilization stage, can significantly improve IL-10 level in patients, reduce TNF-alpha, IL-32 and IL-17 level, and possibly relieve airway or lung inflammatory reaction, thereby relieving or inhibiting disease progression.
(1) IL-10 level comparison
(2) Comparison of TNF-alpha levels
(3) IL-32 level comparison
(4) IL-17 level comparison
The medicine composition can effectively play the roles of immunoregulation and inflammation inhibition, and has the mechanisms of reducing the expression of serum inflammatory factors TNF-alpha, IL-beta, IL-6, IFN-gamma, IL-17 and the like, promoting the secretion of anti-inflammatory factors IL-4 and IL-35, regulating the balance of Th1/Th2, enhancing the immunity, reducing the lung inflammatory reaction, reducing the acute weighting times and improving the life quality.
In this example, the pharmaceutical composition intervenes in experimental study of a rat model of COPD;
establishment of COPD (COPD) symptoms combined with animal models
After the SPF SD rats are adaptively fed, the SPF SD rats are randomly divided into a normal group, a lung-kidney qi deficiency syndrome model group and a treatment group, and 20 rats in each group.
The COPD rat model with lung and kidney qi deficiency syndrome is replicated by combining fumigation with LPS (lipopolysaccharide) trachea instillation and forced swimming and hormone injection. The rats were forced swim for 30 minutes in a constant temperature water tank (43+ -1deg.C) before smoking every day to consume their lung gas, then placed in a self-made smoking box, smoked by burning 50g of sawdust and 10 cigarettes for 1 time every day for 30 minutes, smoked for 28 days, exposed air tube through surgery on day 1, 14 days, 200 μl LPS (1 mg/mL) was added to each rat air tube, smoking was not carried out on the day, smoking was carried out 3 times per day instead, and hydrocortisone sodium succinate 0.3 mL/day (25 mg/mL) was continuously injected subcutaneously on the back, once daily for 8 days.
The administration method is that the administration is started after the 2 nd instillation of LPS, after the molding is carried out every day, the treatment group is subjected to gastric lavage administration according to the dosage of 4.95g/kg, and the administration dosage is converted according to the clinical equivalent dosage for 1 time every day until the molding is finished; normal rats and model rats were given equal volumes of saline for lavage.
The mechanism of action of the pharmacological effect of the pharmaceutical composition;
effects of the pharmaceutical composition on pulmonary function and lung pathology in COPD rats each group of rats was observed for lung tissue pathology, as a result, it was found that the alveolar walls of COPD rats become thin, ruptured, and inflammatory cell infiltrated; the alveolar structure, inflammatory cell infiltration and the like of rats in the treatment group are improved, and AMLI is obviously reduced. Compared with normal group rat lung function, COPD group rat lung function was significantly reduced (P < 0.05); compared with the lung function of rats in COPD group, the lung function of rats in treatment group is reduced, and the difference has statistical significance.
Compared with normal rats, the effect of the serum IL1B, TNF-alpha and NF kappa B expression of the rats in the COPD group is obviously increased, and the serum IL1B, TNF-alpha and NF kappa B level of the rats in the COPD group is obviously increased; IL1B, TNF-alpha, NF- κB expression was reduced in the serum of rats in the treatment group compared to the COPD group.
Effects of pharmaceutical composition on COPD rat lung tissue IκBα, JNK, cJUN, c-FOS protein expression immunohistochemical results show that compared with normal rats, COPD rats lung tissue JNK, c-JUN, c-FOS protein expression is significantly increased (P < 0.01), IκBα expression is significantly reduced; compared with the rats in the COPD group, the lung tissue of the rats in the treatment group has obviously increased IκBα expression and obviously reduced JNK, c-JUN and c-FOS protein expression.
And detecting the expression of the lncRNA and mRNA of rat lung tissues with the syndrome of COPD lung qi deficiency by adopting a high-throughput sequencing technology to obtain a large number of differentially expressed lncRNA and mRNA, wherein the large number of differentially expressed lncRNA and mRNA comprises 1302 upregulated mRNA,824 downregulated mRNA,718 upregulated lncRNA and 561 downregulated lncRNA. KEGG function enrichment research is carried out on the differential mRNA, and a remarkably enriched B cell receptor signal pathway, an NF- κB signal pathway, an PI3K-AKT signal pathway and other inflammatory immune related signal pathways, and a fat digestion absorption and energy metabolism metabolic signal pathway and other metabolic signal pathways are obtained. The result suggests that the inflammatory immune metabolism network has important influence on the occurrence and development of COPD, and the interaction relationship of lncRNA-mRNA-inflammatory immune metabolism is initially established through interaction analysis.
In the embodiment, the pharmaceutical composition regulates and controls the observation and research of the slow-blocking lung-intestine microecological axis; bacterial total deoxyribonucleic acid (DNA) is extracted from fecal samples and induced sputum samples of COPD patients, species annotation and evaluation, sample comparison analysis, species difference analysis and clinical factor correlation analysis are carried out by using QIIME software through 16S targeted amplification and sequencing, and differences in intestinal microecological diversity of pure western medicine treatment and medicine composition treatment of COPD patients, differential bacterial species in intestinal flora before and after treatment of COPD patients by combining the medicine composition and microbial populations related to clinical factors are searched. By observing the changes of lung and intestine microecology of a patient with COPD before and after treatment, the relationship between the pharmaceutical composition and the intestinal microecology structure and diversity are described based on the changes. The pharmaceutical composition can regulate the expression of specific microbial flora of the microecological lung-intestinal axis by mediating the polarization of alveolar macrophages, target inflammatory immune pathways, consolidate and strengthen the immunity of organisms, and intervene in the inflammatory progress of COPD so as to treat the chronic obstructive pulmonary disease.
The foregoing has shown and described the basic principles and main features of the present invention and the advantages of the present invention. It will be understood by those skilled in the art that the present invention is not limited to the embodiments described above, and that the above embodiments and descriptions are merely illustrative of the principles of the present invention, and various changes and modifications may be made without departing from the spirit and scope of the invention, which is defined in the appended claims. The scope of the invention is defined by the appended claims and equivalents thereof. It is noted that relational terms such as first and second, and the like, if any, are used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Moreover, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus. Without further limitation, an element defined by the phrase "comprising one … …" does not exclude the presence of other like elements in a process, method, article, or apparatus that comprises the element.
Claims (8)
1. A pharmaceutical composition for treating chronic obstructive pulmonary disease, which is characterized in that: the composition comprises the following components: ginseng, astragalus root, fructus alpiniae oxyphyllae, fragrant solomonseal rhizome, dried orange peel and cinnamon.
2. A pharmaceutical composition for treating chronic obstructive pulmonary disease according to claim 2, wherein: the weight portion ratio of each component is as follows: 15-25 parts of ginseng, 7-15 parts of astragalus, 7-15 parts of fructus alpiniae oxyphyllae, 7-15 parts of radix polygonati officinalis, 4-10 parts of dried orange peel and 1-5 parts of cinnamon.
3. A pharmaceutical composition for treating chronic obstructive pulmonary disease according to claim 2, wherein: the preferable weight proportion is as follows: 20 parts of ginseng, 10 parts of astragalus, 10 parts of fructus alpiniae oxyphyllae, 10 parts of polygonatum odoratum, 6 parts of dried orange peel and 3 parts of cinnamon.
4. A pharmaceutical composition for treating chronic obstructive pulmonary disease according to claim 1, wherein: the traditional Chinese medicine also comprises dwarf lilyturf tuber, bletilla tuber, pepperweed seed and earthworm, and the traditional Chinese medicine is prepared from the following components in parts by weight: 10 parts of dwarf lilyturf tuber, 10 parts of common bletilla tuber, 6 parts of pepperweed seed and 8 parts of earthworm.
5. Use of a pharmaceutical composition according to any one of claims 1-4 for the preparation of a product for the treatment of chronic obstructive pulmonary disease, characterized in that: can be made into any conventional oral preparation in pharmacy, including but not limited to decoction, granule, pill, tablet, capsule, oral liquid or oral liquid.
6. The method for preparing the traditional Chinese medicine decoction by using the pharmaceutical composition for treating chronic obstructive pulmonary disease according to claim 5, wherein the method is characterized by comprising the following steps: the method comprises the following steps: weighing a proper amount of medicinal composition according to the weight ratio, mixing and crushing the medicinal composition, mixing the medicinal components with water, heating and extracting, wherein the heating and extracting comprises the steps of decocting with strong fire and then decocting with slow fire for two times, mixing the decoctions, filtering the residues to obtain an extracted liquid medicine, namely the decoction.
7. The method for preparing the traditional Chinese medicine particles by using the pharmaceutical composition for treating chronic obstructive pulmonary disease according to claim 5, wherein the method comprises the following steps: the method comprises the following steps: weighing a proper amount of medicinal composition according to the weight ratio, mixing and crushing the medicinal composition, mixing the medicinal components with water, heating and extracting, decocting with strong fire, decocting with slow fire for two times, mixing decoctions, filtering residues to obtain a leaching liquid medicine, concentrating the leaching liquid medicine into thick paste, drying, crushing into fine powder, adding a proper amount of sugar powder and dextrin, mixing uniformly, adding ethanol to prepare a soft material, granulating, drying and finishing to obtain the traditional Chinese medicine granules.
8. A method of preparing a capsule of a pharmaceutical composition for treating chronic obstructive pulmonary according to claim 7, wherein: packaging the above Chinese medicinal granule to obtain capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310736383.8A CN116509973A (en) | 2023-06-21 | 2023-06-21 | Pharmaceutical composition for treating chronic obstructive pulmonary disease and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310736383.8A CN116509973A (en) | 2023-06-21 | 2023-06-21 | Pharmaceutical composition for treating chronic obstructive pulmonary disease and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116509973A true CN116509973A (en) | 2023-08-01 |
Family
ID=87401408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310736383.8A Pending CN116509973A (en) | 2023-06-21 | 2023-06-21 | Pharmaceutical composition for treating chronic obstructive pulmonary disease and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116509973A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104306847A (en) * | 2014-09-10 | 2015-01-28 | 安徽中医药大学第一附属医院 | Six-ingredient qi-tonifying capsule and preparation process thereof |
| CN114558049A (en) * | 2022-03-29 | 2022-05-31 | 安徽中医药大学 | Traditional Chinese medicine prescription for treating Chronic Obstructive Pulmonary Disease (COPD) stable phase series and application |
-
2023
- 2023-06-21 CN CN202310736383.8A patent/CN116509973A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104306847A (en) * | 2014-09-10 | 2015-01-28 | 安徽中医药大学第一附属医院 | Six-ingredient qi-tonifying capsule and preparation process thereof |
| CN114558049A (en) * | 2022-03-29 | 2022-05-31 | 安徽中医药大学 | Traditional Chinese medicine prescription for treating Chronic Obstructive Pulmonary Disease (COPD) stable phase series and application |
Non-Patent Citations (4)
| Title |
|---|
| 刘志刚，等: "六味补气胶囊对肺气虚型慢性阻塞性肺疾病稳定期患者生活质量和肺功能的影响", 安徽中医学院学报, vol. 31, no. 01, 29 February 2012 (2012-02-29), pages 6 * |
| 张至强，等: "金水相生法治疗慢性阻塞性肺疾病稳定期探微", 陕西中医药大学学报, vol. 41, no. 06, 10 November 2018 (2018-11-10), pages 10 - 12 * |
| 曾时杰，等: "六味补气颗粒剂联合舒利迭对COPD稳定期患者免疫功能的影响", 湖北中医杂志, vol. 40, no. 11, 10 November 2018 (2018-11-10), pages 10 - 13 * |
| 杨勤军，等: "中医药治疗慢性阻塞性肺疾病稳定期研究进展", 江西中医药大学学报, vol. 30, no. 05, 10 July 2018 (2018-07-10), pages 113 - 116 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yan et al. | Aqueous extracts of Herba Cistanche promoted intestinal motility in loperamide-induced constipation rats by ameliorating the interstitial cells of cajal | |
| CN107997176A (en) | A kind of stomach strengthening and digestion promoting health food for preventing children's having indigestion apocleisis | |
| CN103272083B (en) | Pharmaceutical composition for preventing and/or treating asthma, its preparation method and application | |
| CN116098964B (en) | Traditional Chinese medicine composition for treating thyroid nodule and preparation and application thereof | |
| CN103989820B (en) | Medicament for treating hyperlipidemia | |
| CN100464745C (en) | Medication composition of acetyl cysteine or its pharmaceutical salt and asarin | |
| CN116509973A (en) | Pharmaceutical composition for treating chronic obstructive pulmonary disease and application thereof | |
| CN105194460A (en) | Traditional Chinese medicine preparation for treating acute episode stage of wind-damp-heat type gout | |
| CN101693077B (en) | Medicament for treating febrile bronchial asthma and chronic bronchitis | |
| CN106581520B (en) | Traditional Chinese medicine granule for treating diffuse interstitial pulmonary fibrosis lung qi deficiency syndrome | |
| CN113813331A (en) | Composition with throat clearing function and preparation method and application thereof | |
| CN111467467A (en) | Application of substance obtained from volatile oil of Zingiberis rhizoma in treating acute pulmonary inflammation | |
| CN113876844B (en) | Pure traditional Chinese medicine Tibetan medicine for treating chronic tracheitis and preparation method and application thereof | |
| CN104857070A (en) | Pharmaceutical composition used for resisting intestinal tract inflammatory injuries, and preparation method and applications thereof | |
| CN115252713B (en) | Traditional Chinese medicine composition for treating obesity and application thereof | |
| CN116870092B (en) | Traditional Chinese medicine composition for treating chronic pharyngitis | |
| CN107213323B (en) | Chinese medicinal compound preparation for nourishing yin, eliminating phlegm, resolving masses and detoxifying and application thereof | |
| CN102626464B (en) | Medicinal composition for treating chronic pharyngitis and preparation method and application thereof | |
| CN103041160B (en) | Traditional Chinese medicine composition for curing acute pharyngitis and preparation method thereof | |
| CN115400161B (en) | Traditional Chinese medicine composition for treating summer-heat dampness cold and preparation method thereof | |
| CN114259523B (en) | Traditional Chinese medicine composition and application thereof in preparation of medicine for treating cough variant asthma | |
| CN108310206B (en) | Traditional Chinese medicine composition for preventing or treating osteoporosis and preparation method and application thereof | |
| CN104887967A (en) | Traditional Chinese medicine composition for treating ulcerative colitis and preparation method thereof | |
| CN117338875A (en) | Application of pholidota chinensis in preparing medicament for treating diabetes kidney diseases | |
| CN115531501A (en) | Application of Jinfeng diabetes compound preparation in preparation of medicine for treating non-alcoholic fatty liver disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |